CG Oncology (CGON) Net Income towards Common Stockholders (2023 - 2026)

CG Oncology (CGON) has 4 years of Net Income towards Common Stockholders data on file, last reported at -$443.0 million in Q1 2026.

• Quarterly Net Income towards Common Stockholders fell 263.8% year-over-year to -$443.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$866.6 million (down 349.3% YoY) and the FY2025 annual result came in at -$161.0 million, down 82.87% from the prior year.
• Net Income towards Common Stockholders retreated to -$443.0 million in Q1 2026, from -$41.0 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of -$12.4 million in Q1 2023 to a low of -$443.0 million in Q1 2026.
• A 4-year average of -$88.0 million and a median of -$22.5 million in 2023 frame the typical range for Net Income towards Common Stockholders.
• Annual changes were most pronounced in 2024 — Net Income towards Common Stockholders fell 16.51% — and 2025, when it plunged 1048.9%.
• Tracing CGON's Net Income towards Common Stockholders over 4 years: stood at -$22.5 million in 2023, then plunged by 41.39% to -$31.8 million in 2024, then fell by 28.86% to -$41.0 million in 2025, then plunged by 981.1% to -$443.0 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$443.0 million (Q1 2026), -$41.0 million (Q4 2025), and -$234.4 million (Q3 2025), per Business Quant data.